NCT04967079View on ClinicalTrials.gov

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

July 1, 2023

Study Completion Date

March 26, 2024

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Trametinib

Trametinib 2 mg given orally, once daily

DRUG

Anlotinib

Anlotinib given orally, every two weeks followed by a one-week discontinuation cycle

Trial Locations (1)

200000

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Chest Hospital

OTHER

NCT04967079 - Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients | Biotech Hunter | Biotech Hunter